Stock analysts at Mizuho started coverage on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a report released on Wednesday, September 6th, MarketBeat.com reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Mizuho’s price objective would indicate a potential upside of 37.39% from the company’s previous close.
Several other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Canaccord Genuity set a $65.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th. HC Wainwright set a $69.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Finally, BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $66.36.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02.
WARNING: This report was posted by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/aerie-pharmaceuticals-inc-aeri-now-covered-by-mizuho/1615818.html.
Several institutional investors and hedge funds have recently bought and sold shares of AERI. Quantbot Technologies LP acquired a new stake in shares of Aerie Pharmaceuticals in the 1st quarter worth about $107,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Aerie Pharmaceuticals in the 1st quarter worth about $108,000. BNP Paribas Arbitrage SA raised its holdings in shares of Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. BlueCrest Capital Management Ltd purchased a new stake in Aerie Pharmaceuticals in the 1st quarter valued at about $202,000. Finally, Amalgamated Bank purchased a new stake in Aerie Pharmaceuticals in the 2nd quarter valued at about $204,000. Institutional investors own 94.64% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.